Remy Sukhija Net Worth

The estimated Net Worth of Remy Sukhija is at least $7.7 Milhão dollars as of 23 December 2022. Mr Sukhija owns over 30,000 units of Madrigal Pharmaceuticals Inc stock worth over $6,990,000 and over the last 4 years he sold MDGL stock worth over $0. In addition, he makes $714,902 as Sr. VP & Chief Commercial Officer at Madrigal Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Sukhija MDGL stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Madrigal Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of MDGL stock worth $1,807,800 on 23 December 2022.

The largest trade he's ever made was exercising 30,000 units of Madrigal Pharmaceuticals Inc stock on 23 December 2022 worth over $1,807,800. On average, Mr trades about 7,500 units every 0 days since 2021. As of 23 December 2022 he still owns at least 30,000 units of Madrigal Pharmaceuticals Inc stock.

You can see the complete history of Mr Sukhija stock trades at the bottom of the page.

Mr. Remy Sukhija biography

Remy Sukhija is the Sr. VP & Chief Commercial Officer at Madrigal Pharmaceuticals Inc.

What is the salary of Mr Sukhija?

As the Sr. VP & Chief Commercial Officer of Madrigal Pharmaceuticals Inc, the total compensation of Mr Sukhija at Madrigal Pharmaceuticals Inc is $714,902. There are 7 executives at Madrigal Pharmaceuticals Inc getting paid more, with Paul Friedman having the highest compensation of $6,093,190.

How old is Mr Sukhija?

Mr Sukhija is 49, he's been the Sr. VP & Chief Commercial Officer of Madrigal Pharmaceuticals Inc since . There are 16 older and 1 younger executives at Madrigal Pharmaceuticals Inc. The oldest executive at Madrigal Pharmaceuticals Inc is David Milligan, 79, who is the Independent Director.

What's Mr Sukhija's mailing address?

Remy's mailing address filed with the SEC is C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN, PA, 19428.

Insiders trading at Madrigal Pharmaceuticals Inc

Over the last 8 years, insiders at Madrigal Pharmaceuticals Inc have traded over $471,222,585 worth of Madrigal Pharmaceuticals Inc stock and bought 443,785 units worth $79,114,183 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Paul A Friedman, eBros. Advisors Lp667, L.P.B.... On average, Madrigal Pharmaceuticals Inc executives and independent directors trade stock every 56 days with the average trade being worth of $20,602,093. The most recent stock trade was executed by William John Sibold on 9 September 2024, trading 6,363 units of MDGL stock currently worth $1,551,490.

What does Madrigal Pharmaceuticals Inc do?

madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.

Complete history of Mr Sukhija stock trades at Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc executives and stock owners

Madrigal Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Paul Friedman,
  Chairman of the Board, Chief Executive Officer
• Rebecca Taub,
  President of Research and Development, Chief Medical Officer, Director
• Brian Lynch,
  Senior Vice President, General Counsel
• Marc Schneebaum,
  Chief Financial Officer, Senior Vice President
• James Daly,
  Independent Director
• Dr. Paul A. Friedman M.D.,
  Chairman & CEO
• Dr. Rebecca A. Taub M.D.,
  Founder, Chief Medical Officer, Pres of R&D and Director
• Remy Sukhija,
  Sr. VP & Chief Commercial Officer
• Brian J. Lynch J.D.,
  Sr. VP & Gen. Counsel
• Brian J. Lynch,
  Sr. VP & Gen. Counsel
• Kenneth Bate,
  Independent Director
• Richard Levy,
  Independent Director
• Keith Gollust,
  Independent Director
• David Milligan,
  Independent Director
• Frederick Craves,
  Lead Independent Director
• Remy Sukhija,
  Senior Vice President, Chief Commercial Officer
• Edward Chiang,
  Sr. VP of Clinical & Technical Operations
• Dr. Stephen Dodge M.B.A., Pharm.D.,
  Sr. VP & Global Head of Medical Affairs
• Dr. Robert E. Waltermire Ph.D.,
  Chief Pharmaceutical Devel. Officer
• Thomas W. Hare,
  Sr. VP of Clinical Management
• Dr. Kianoush Motesharei Ph.d.,
  Sr. VP of Bus. & Corp. Devel.
• Alex G. Howarth,
  Chief Financial Officer
• Bros. Advisors Lp667, L.P.B...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Chen Schor,
  Former President and CEO
• Wendy E Rieder,
  Former SVP, Gen. Counsel
• City Capital Llc Bay,
  Director
• City Capital Llc Bay City C...,
  
• Alex G. Howarth,
  Chief Financial Officer
• Robert E. Waltermire,
  Senior VP, Chief Pharma Dev.
• Bros. Advisors Lp Baker,
  
• Shannon T Kelley,
  General Counsel
• William John Sibold,
  President and CEO
• Carole Huntsman,
  Chief Commercial Officer
• Fred B Craves,